Independent narrative evidence note · not a systematic review or clinical study

VR Immersion vs Ketamine Dissociation

A cautious comparison of immersive virtual reality and ketamine-associated dissociation, with direct combined-use evidence separated from conceptual analogy and ongoing trials.

Joe Nasr / QuestRequestVR · immersive perception / VR neuroscience / human-computer interaction · updated 17 September 2026

Research question

What similarities and differences are defensible when comparing VR immersion and presence with ketamine-associated dissociative experiences, and what evidence exists for using VR during ketamine or esketamine treatment?

Evidence boundary: direct combined-use evidence is sparse but real. Published case-level evidence and several registered studies exist, including completed and recruiting trials. That does not establish that VR and ketamine produce equivalent states, nor does it establish a mature evidence base for therapeutic synergy.

What is reasonably supported

Virtual reality

VR can manipulate sensory input, attention, embodiment and presence through an external interactive environment. The experience is mediated by hardware/software and depends heavily on content, interaction design and individual response.

Ketamine and esketamine

Ketamine is an NMDA-receptor antagonist whose current U.S. injection labeling is for anesthesia. Ketamine is also studied and used off-label in some psychiatric settings. Intranasal esketamine has separate approved U.S. psychiatric indications. Dissociative and psychedelic-like experiences can occur during ketamine/esketamine exposure, but these are pharmacological effects rather than externally generated sensory simulation.

Comparison without false equivalence

Dimension	VR immersion / presence	Ketamine-associated dissociation
Primary driver	External sensory and interactive mediation	Pharmacological action, including NMDA-receptor antagonism
Self/world perception	Can alter presence, embodiment and perceived environment	Can produce dissociation, depersonalization, derealization and other altered experiences
Control	Usually content- and device-mediated; exposure can generally be stopped by removing the interface	Drug effects persist according to pharmacology, dose and clinical context
Clinical status	Studied across exposure therapy, rehabilitation, procedural pain/distraction and other applications	Ketamine injection is labeled for anesthesia in the U.S.; intranasal esketamine has defined U.S. psychiatric indications
Equivalence	Not established. Shared descriptive language about altered perception does not imply common mechanism or interchangeable experience.

Direct combined-use evidence

Published clinical evidence

Maani et al. (2011) reported two severe-burn patients who received ketamine during wound care and were compared within-session with and without immersive VR. Both patients reported lower pain ratings during the ketamine + VR condition. This is direct combined-use evidence, but it is a two-patient case report and cannot establish general efficacy or synergy. PubMed 21481162.

Completed registered studies

NCT01889537 — Low Dose Ketamine VR Analgesia During Burn Care Procedure. Completed Phase 2 study; registry enrollment was 3 participants. The registry does not provide posted efficacy results. ClinicalTrials.gov.
NCT06139016 — Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment. Yale University; completed; actual enrollment 7. The registry contains posted results and measures tolerability, safety, treatment experience, altered-state measures and dissociation. No linked peer-reviewed publication was listed in the registry at this audit. ClinicalTrials.gov.

Ongoing registered studies

NCT06781697 — TREASURE. Sunnybrook Health Sciences Centre; recruiting pilot randomized trial in treatment-resistant depression comparing concurrent IV ketamine + immersive VR with ketamine alone. Estimated enrollment: 31. Primary outcomes are feasibility; secondary outcomes include depression, anxiety, dissociation, cognition, EEG and VR tolerability. No results are posted. ClinicalTrials.gov.
NCT07422519 — VR-based mindfulness + esketamine. Recruiting randomized study in treatment-resistant depression comparing VR-based mindfulness plus treatment as usual with treatment as usual alone; esketamine is part of the treatment-as-usual pathway. No results are posted. ClinicalTrials.gov.

Registered-study status describes what researchers planned or conducted; it does not by itself establish efficacy, safety or clinical usefulness.

What the evidence does not yet establish

No mature evidence base establishes that VR is a substitute for ketamine or reliably reproduces ketamine-associated dissociation.
The evidence reviewed here does not establish a general antidepressant synergy between VR and ketamine/esketamine.
The completed Yale study and ongoing trials show that the question is being tested; they do not justify treating the answer as settled.
No universal response-rate figure for a combined VR-ketamine intervention is justified from the evidence reviewed here.

Literature anchors

Maani CV et al. (2011). Combining ketamine and virtual reality pain control during severe burn wound care: one military and one civilian patient. Direct two-patient combined-use case report. PubMed 21481162.
Marguilho M, Figueiredo I, Castro-Rodrigues P. (2023). A unified model of ketamine's dissociative and psychedelic properties. Review discussing ketamine's dissociative/psychedelic effects across molecular, network and psychological levels. PubMed 36527355.
Petrucci ABC et al. (2024). Ketamine versus electroconvulsive therapy for major depressive episode: An updated systematic review and non-inferiority meta-analysis. Includes dissociative symptoms among safety outcomes. PubMed 38865906.
Man DWK. (2020). Virtual reality-based cognitive training for drug abusers: A randomised controlled trial. Studied VR cognitive training in young ketamine users; it did not test simultaneous VR plus ketamine treatment. PubMed 29734923.
Sekula AD, Downey L, Puspanathan P. (2022). Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. Conceptual/review paper that explicitly described combined VR + psychedelic-assisted psychotherapy evidence as speculative at that time. PubMed 35310225.

Search audit

Evidence was re-audited on 17 September 2026 using PubMed, ClinicalTrials.gov and current U.S. DailyMed labels. Targeted searches combined virtual reality / VR with ketamine / esketamine.

This remains a narrative evidence note, not a systematic review. It does not claim exhaustive database coverage, formal risk-of-bias assessment, protocol registration, duplicate screening or PRISMA-compliant study selection.

Research status and limitations

Status: independent narrative evidence note.

The direct literature is still too small and heterogeneous for a broad efficacy conclusion. Published evidence includes case-level combined-use data; registry evidence shows completed and ongoing clinical investigation. Those evidence types must remain separate.

Safety

This page does not recommend ketamine or esketamine use, self-experimentation, dosing or treatment. Clinical use belongs under qualified medical supervision and authoritative medical guidance.